Syndax Q2 net loss $37.6M ($0.62/sh); on track for pivotal data in 1H23

Syndax Pharmaceuticals Inc

2022-Q2 EPS reported -$1.25

Cash $378.9M; net loss $37.6M ($0.62/sh) vs $22.9M ($0.44/sh) year ago.
R&D expenses $29.7M (up from $16.9M); G&A $8.0M (up from $5.8M).
On track to report topline data from revumenib and axatilimab pivotal programs in 1H23.
Updated revumenib Phase 1 data expected 4Q22; axatilimab IPF trial start in 4Q22.
Appointed Keith A. Goldan as CFO in June 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.